Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Bellon Christine

2. Date of Event Requiring Statement (MM/DD/YYYY) 3/16/2023

3. Issuer Name and Ticker or Trading Symbol

Beam Therapeutics Inc. [BEAM]

(Last) (First) (Middle)

C/O BEAM THERAPEUTICS INC., 238 MAIN STREET

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
Chief Legal Officer /

(Street)

CAMBRIDGE, MA 02142

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	58441 ⁽¹⁾⁽²⁾	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽³⁾	3/31/2031	Common Stock	23959 ⁽⁴⁾	$80.04	D
Stock Option (Right to Buy)	⁽⁵⁾	1/31/2032	Common Stock	30000	$69.21	D
Stock Option (Right to Buy)	⁽⁶⁾	1/31/2033	Common Stock	35000	$43.45	D
Stock Option (Right to Buy)	⁽⁷⁾	5/16/2029	Common Stock	19946 ⁽⁸⁾	$7.22	D
Stock Option (Right to Buy)	⁽⁹⁾	5/17/2029	Common Stock	19405 ⁽¹⁰⁾	$7.22	D
Stock Option (Right to Buy)	⁽¹¹⁾	8/31/2031	Common Stock	10000	$110.92	D
Stock Option (Right to Buy)	⁽¹²⁾	12/30/2032	Common Stock	25000	$39.11	D

Explanation of Responses:
(1)	Includes 9,375, 3,750, 15,000 and 12,500 restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's 2019 Equity Incentive Plan on March 31, 2021, September 30, 2021, March 31, 2022 and December 30, 2022, respectively.
(2)	Each RSU represents the contingent right to receive one share of the Issuer's common stock. The March 31, 2021, September 30, 2021 and March 31, 2022 RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with the Issuer through each vesting date. The December 30, 2022 RSUs vest in three substantially equal installments on each of the first three anniversaries of the grant date, subject to the Reporting Person's continued service with the Issuer through each vesting date. The March 31, 2021 RSUs grant was originally for 12,500 RSUs of which 3,125 RSUs have already vested. The September 30, 2021 RSUs grant was originally for 5,000 RSUs of which 1,250 RSUs have already vested.
(3)	The option vests at a rate of 2.08% each month until the option is fully vested.
(4)	The option grant was originally for options to purchase 25,000 shares of the Issuer's common stock of which 1,041 have already been exercised.
(5)	The option vests at a rate of 2.08% each month until the option is fully vested.
(6)	The option vests at a rate of 2.08% each month thereafter until the option is fully vested.
(7)	The option vests as to 25% on the first anniversary of the vesting commencement date, May 16, 2020, and at a rate of 2.78% each month thereafter until the option is fully vested.
(8)	The option grant was originally for options to purchase 100,350 shares of the Issuer's common stock of which 80,404 have already been exercised.
(9)	The option vests as to 25% on the first anniversary of the vesting commencement date, May 17, 2020, and at a rate of 2.78% each month thereafter until the option is fully vested.
(10)	The option grant was originally for options to purchase 42,704 shares of the Issuer's common stock of which 23,299 have already been exercised.
(11)	The option vests at a rate of 2.08% each month thereafter until the option is fully vested.
(12)	The option vests at a rate of 2.78% each month until the option is fully vested.

Remarks:
Exhibit List: Exhibit 24 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Bellon Christine C/O BEAM THERAPEUTICS INC. 238 MAIN STREET CAMBRIDGE, MA 02142			Chief Legal Officer

Signatures
By: /s/ Christine Bellon		3/27/2023
^**Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.